Primer probe group, kit and detection method for detecting twelve respiratory pathogens

By designing a primer probe set and kit for twelve respiratory pathogen detection, using nucleic acid release agents and fast fluorescence PCR technology, the problems of narrow coverage, long detection time and complex operation in the existing technology are solved, and the diversity is achieved Rapid and efficient detection of chemical infection.

CN119020535APending Publication Date: 2024-11-26上海邦先医疗科技有限公司
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411238996.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing respiratory pathogen detection products have a narrow coverage, long detection time and complex operation, which cannot meet the clinical needs for diversified infections and the requirements for rapid detection.

Method used

A primer probe set and kit for twelve respiratory pathogen detection was designed, using nucleic acid release agents instead of the nucleic acid extraction process, combined with a fast fluorescence PCR system, to provide a lyophilized detection kit to simplify operation and shorten detection time.

Benefits of technology

High sensitivity and specific detection of twelve common respiratory pathogens has been achieved, shortening the detection time to 50 minutes, reducing operational complexity and technical requirements, and improving detection efficiency and sensitivity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of pathogen detection, and discloses a kit for detecting twelve respiratory pathogens, which adopts a primer probe group for detecting the twelve respiratory pathogens and comprises PCR freeze-drying balls 1-4, a negative reference substance and a positive reference substance, wherein the PCR freeze-drying balls 1-4 comprise a primer probe group. The primer probe group for detecting the twelve respiratory pathogens is high in sensitivity, good in specificity and wide in pathogen coverage range, and can meet the clinical requirements of diversified infection of the respiratory pathogens at present.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pathogen detection, and in particular to a primer probe set, a kit and a detection method for detecting twelve respiratory pathogens. Background Art

[0002] Respiratory tract infection (RTI) is the most common type of disease in humans. It can occur in any gender, age and region, and is one of the main causes of morbidity and mortality in the world. The clinical symptoms and signs caused by respiratory tract infection are relatively similar. Its clinical manifestations are mainly rhinitis, pharyngitis, laryngitis, tonsillitis and other symptoms. Severe cases can cause tracheitis, bronchitis and pneumonia, but the treatment methods, efficacy and course of infection caused by different pathogens are also different. It has been proven that most respiratory diseases are caused by pathogens other than bacteria, among which respiratory viruses are the most common. Common respiratory pathogens include influenza A virus, influenza B virus, adenovirus, new coronavirus, coronavirus, respiratory syncytial virus, rhinovirus, parainfluenza virus, Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptococcus pneumoniae, Haemophilus influenzae, Mycobacterium tuberculosis, Klebsiella pneumoniae and more than a dozen other types.

[0003] At present, antigen detection is still the most common method used in clinical identification of respiratory pathogens. However, with the development of molecular detection technology in recent years, more and more nucleic acid detection products based on the principle of fluorescent PCR technology have been widely used in the detection of respiratory pathogens. Compared with antigen detection methods, their window period is shorter and their sensitivity is higher.

[0004] Fluorescence PCR technology is currently the most widely used detection technology in the field of molecular diagnosis. Due to its high detection sensitivity and strong specificity, it is widely used in many fields such as pathogen detection, early tumor screening, and food testing. Its core principle is PCR amplification and fluorescence signal detection. The PCR amplification process simulates the semi-conservative replication process of DNA in the body. In the presence of biological enzymes, dNTPs, metal ions and other substances, the primers that are complementary to the target gene nucleic acid sequence are used as guides to synthesize new nucleic acid fragments. The reaction conditions include denaturation, annealing and extension. The fluorescent signal is detected by a probe that is complementary to the target sequence and labeled with a reporter group and a quencher group at the 5' and 3' ends respectively. Common probes include the most commonly used Taqman probes, molecular beacon probes, scorpion probes, MGB probes, etc. Different types of probes are used in different specific detection fields.

[0005] Currently, there are relatively few respiratory pathogen detection products based on fluorescent PCR technology on the market, which mainly include two product forms: a) single pathogen detection; b) combined detection of multiple pathogens, generally 3 to 6. The detection process mainly includes: a) collection of clinical nasopharyngeal swab and oropharyngeal swab samples; b) nucleic acid extraction of samples to obtain purified pathogen nucleic acid; c) fluorescent PCR detection of the presence of pathogen nucleic acid.

[0006] However:

[0007] 1) Most existing products can only cover one respiratory pathogen, and a few can cover 3 to 6 pathogens, with a narrow coverage range. However, the prevalence of respiratory pathogens in clinical practice is more complex and diverse, and a single product may no longer be able to meet clinical testing needs.

[0008] 2) The testing time of existing products is too long. The nucleic acid extraction time is about 30 minutes, and the PCR testing process takes 1 to 2 hours. Patients have to wait a long time from sampling to getting the test report and asking the doctor to prescribe a treatment plan, which provides a poor user experience.

[0009] 3) The operation is complicated. Existing products basically adopt the traditional reagent component model. The detection process requires manual sample addition and processing, which is cumbersome and requires high professional technical capabilities of the operator. Summary of the invention

[0010] The purpose of the present invention is to solve the problems existing in the prior art and to propose a primer probe set, a kit and a detection method for twelve respiratory pathogens detection.

[0011] In order to achieve the above object, the present invention adopts the following technical solutions:

[0012] A twelve-panel respiratory pathogen test primer probe set, including:

[0013] Influenza A virus targets, including:

[0014] Upstream primer 5′-GGAGTYTTCGAGCTYTCRGAC-3′;

[0015] Downstream primer 5′-TCTGCATTGTCTCCRAAGAAATARG-3′;

[0016] Probe 5'5'-FAM-CCGATCGTGCCYTCYTTTGACATGA-3'BHQ1

[0017] Influenza B virus targets, including:

[0018] Upstream primer 5′-CTGAAACTGCGRTGGGAGTC-3′;

[0019] Downstream primer 5′-TTGTCTCCCTCTTCTGGTGAT-3′;

[0020] Probe 5′5′-ROX-TCCCAATTTGGTCAAGAGCACCGATT-3′BHQ2;

[0021] Adenoviral targets include:

[0022] Upstream primer 5′-GCTCCATGGCCTCRTARAAG-3′;

[0023] Downstream primer 5′-CGARCTCATCCGTCTTYTSG-3′;

[0024] Probe 5′CY5-CCACGGCRAARTTRAAAAACTGGGAGTT-3′BHQ3;

[0025] Novel coronavirus targets, including:

[0026] Upstream primer-15′-TCATCAGGAGATGCCACAAC-3′;

[0027] Downstream primer-15′-CGGCAATTTTGTTACCATCA-3′;

[0028] Probe-1 5′FAM-CTGTCACGGCCAATGTTAATGCA-3′BHQ1;

[0029] Upstream primer-25′-GTGATGCTGCTCTTGCTTTG-3′;

[0030] Downstream primer-25′-CCTTGTTGTTGTTGGCCTTT-3′;

[0031] Probe-2 5'5'-FAM-TGACAGATTGAACCAGCTTGAGAGCA-3'BHQ1; Coronavirus targets, including:

[0032] Upstream primer-15′-TTWTCTATCTAYAGATAGARAAKTT-3′;

[0033] Downstream primer-15′-GAAATTTCAATTACACTASGACT-3′;

[0034] Probe-1 5'5'-ROX-TTTAGACTTTGTGTCTACTYTTCTCAACT-3'BHQ2; Upstream primer-2 5'-CRCCTGTACAGGTTGTTGATTC-3';

[0035] Downstream primer-25′-CCATCWCCRTGRTTAATATCATA-3′;

[0036] Probe-2 5'5'-ROX-CCRTAYTGTTATTTTCGYAATTCTWCT-3'BHQ2; Respiratory Syncytial Virus target, including:

[0037] Upstream primer 5′-GGGCAAATATGGAAACDTACGTG-3′;

[0038] Downstream primer 5′-GATGCRGGRTCATCRTCTTTTTC-3′;

[0039] Probe 5′CY5-CTTCACGARGGCTCCACATACACAGC-3′BHQ3;

[0040] Rhinovirus targets, including:

[0041] Upstream primer 5′-GCCTGCGTGGCGGCCARC-3′;

[0042] Downstream primer 5′-CCCAAAGTAGTYGGTYCCRTC-3′;

[0043] Probe 5'FAM-TCCGGYCCCTGAATGYGGCTAA-3'BHQ1;

[0044] Parainfluenza virus targets, including:

[0045] Upstream primer-15′-TTTCTTAYAGTCTCAAAGAAAARG-3′;

[0046] Downstream primer-15′-ATCTCTCCCTTCACCATCCCATT-3′;

[0047] Probe-1 5′ROX-AACAAGARGGTAGACTCTTTGCAAARATGACA-3′BHQ2; Upstream primer-2 5′-AAATACTGTCTTMAWTGGAGATATC-3′;

[0048] Downstream primer-25′-ATGAATCCAYTCAAATAAATGWGG-3′;

[0049] Probe-2 5'5'-ROX-TTTGCTMGAACATTAAAYCGAATGTATGGA-3'BHQ2; Mycoplasma pneumoniae targets, including:

[0050] Upstream primer 5′-GTTGTTGGTGGARGAGGTGT-3′;

[0051] Downstream primer 5′-CCCGTTGAAAAAGTGAGTGG-3′;

[0052] Probe 5′CY5-CTTGGTAACTGCCCCACAAGCCAC-3′BHQ3;

[0053] Chlamydia pneumoniae targets, including:

[0054] Upstream primer 5′-AAGGGCTATAAAGGCGTTGCT-3′;

[0055] Downstream primer 5′-TGGTCGCAGACTTTGTTCCA-3′;

[0056] Probe 5′FAM-TCCCCTTGCCAACAGACGCTGG-3′BHQ1;

[0057] Streptococcus pneumoniae targets, including:

[0058] Upstream primer 5′-CCAACAAATCGTTTACCGCTC-3′;

[0059] Downstream primer 5′-TGGTTTGGCAAGTAGCGATAG-3′;

[0060] Probe 5′ROX-CACTCGAATTGCTGGGGTCTTCCACT-3′BHQ2;

[0061] Haemophilus influenzae targets, including:

[0062] Upstream primer 5′-GCCAAGAGATACTCATAGAACGT-3′;

[0063] Downstream primer 5′-TTTAGGGCGAAATGGTGCTG-3′;

[0064] Probe 5′CY5-TTGGAGGCTCAACACCASTCATCAAA-3′BHQ3;

[0065] RNaseP gene targets, including:

[0066] Upstream primer 5′-TTCTGGGGGTTGTTATCTGG-3′;

[0067] Downstream primer 5′-TCCGGCTTCTGTCACCTATC-3′;

[0068] Probe 5'VIC-AACGAGGGCGAGGGATTTGCAT-3'BHQ1.

[0069] A kit for detecting twelve respiratory pathogens, using a primer probe set for detecting twelve respiratory pathogens, including PCR freeze-dried balls 1 to 4, a negative control substance, and a positive control substance;

[0070] The PCR freeze-dried balls 1 to 4 include primer probe sets.

[0071] Preferably, the PCR freeze-dried pellet further comprises at least one of PCR Buffer, Taq enzyme, UDG enzyme and reverse transcriptase.

[0072] Preferably, the negative control is physiological saline containing human genomic DNA.

[0073] Preferably, the positive control is a physiological saline containing human genomic DNA, influenza A virus, influenza B virus, adenovirus, novel coronavirus, coronavirus, respiratory syncytial virus, rhinovirus, parainfluenza virus, Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptococcus pneumoniae, Haemophilus influenzae plasmid or pseudovirus.

[0074] Preferably, in the PCR freeze-dried balls 1 to 4, the final concentration of the primers is 0.1 to 0.4 μM, and the final concentration of the probes is 0.05 to 0.2 μM.

[0075] A method for detecting twelve respiratory pathogens, using a kit for detecting twelve respiratory pathogens, comprises the following steps:

[0076] a) Collect samples according to the standard sampling operation method for nasopharyngeal swabs and oropharyngeal swabs, and store them in nucleic acid release agents for later use;

[0077] b) Add the negative control substance, positive control substance and nucleic acid releasing agent in the kit in a ratio of 1:1 and mix well for later use;

[0078] c) taking 20 μl of each sample from step a) and step b) and adding them to the PCR reaction tubes containing freeze-dried balls 1 to 4 to fully dissolve them, flash centrifuging to ensure that there are no bubbles; placing them in a fluorescent quantitative PCR instrument for fluorescent PCR detection;

[0079] d) The reaction program was set as follows: Step 1: 55°C for 2-5 min; Step 2: 98°C for 1 min; Step 3: 98°C for 1-3 s, 60°C for 5-10 s, where Step 3 was set for 40 cycles and fluorescence (FAM / VIC / ROX / CY5) was read during 60°C for 5-10 s;

[0080] e) After PCR amplification, the analysis software of the fluorescent PCR instrument is used to analyze the results of the test samples, negative controls, and positive controls, and the fluorescence signal values ​​of the FAM / VIC / ROX / CY5 channels are used to determine the effectiveness of the experiment and the infection status of the twelve respiratory pathogens in the sample.

[0081] Preferably, the reaction program is set as follows: Step 1: 55°C for 2 min; Step 2: 98°C for 1 min; Step 3: 98°C for 1 s, 60°C for 5 s, wherein Step 3 is set for 40 cycles, and fluorescence (FAM / VIC / ROX / CY5) is read during 60°C for 5 s.

[0082] Compared with the prior art, the present invention has the following beneficial effects:

[0083] The primer probe set for detecting twelve respiratory pathogens provided by the present invention has high sensitivity, good specificity, covers a wide range of pathogens, and can meet the current clinical needs for diversified infections of respiratory pathogens.

[0084] The kit provided by the present invention adopts the form of freeze-dried balls, which is more convenient to transport and store, does not require a complicated manual preparation process, and can be added with a 100% proportion of nucleic acid template, thereby improving the detection sensitivity; the freeze-dried ball reagent adopts an ultrafast PCR reaction system, which can realize a fast fluorescent PCR detection process;

[0085] The present invention provides a detection method for lysing a sample using a nucleic acid releaser, which does not require a cumbersome and time-consuming nucleic acid extraction process; it also provides an amplification procedure with a shorter reaction time. The entire detection process can be completed in about 50 minutes when used with the kit of the present invention, thereby improving the detection efficiency. DETAILED DESCRIPTION

[0086] The technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments.

[0087] Most of the existing products can only cover one respiratory pathogen, and a few can cover 3 to 6 pathogens. The coverage range is relatively narrow. The clinical prevalence of respiratory pathogens is more complex and diverse, and a single product may no longer be able to meet clinical testing needs.

[0088] The testing time of existing products is too long. The nucleic acid extraction time is about 30 minutes, and the PCR testing process takes 1 to 2 hours. Patients have to wait a long time from sampling to getting the test report and asking the doctor to prescribe a treatment plan, which provides a poor experience.

[0089] The operation is complicated. Existing products basically adopt the traditional reagent component model. The detection process requires manual sample addition and processing, which is cumbersome and requires high professional and technical capabilities of the operator.

[0090] Therefore, the first purpose of the present invention is to solve the shortcomings of existing products that cover fewer types of pathogens, and to simultaneously detect and differentiate twelve common respiratory pathogens.

[0091] The second purpose of the present invention is to use a nucleic acid releaser to replace the nucleic acid extraction process, so that nucleic acid extraction is not required and it can be directly used for subsequent fluorescent PCR detection; at the same time, a rapid fluorescent PCR system is adopted, which can complete the entire detection process in about 50 minutes.

[0092] The third object of the present invention is to provide a freeze-dried detection kit, which does not require additional manual operation, and the extracted nucleic acid can be directly added to the freeze-dried reagent for detection. At the same time, the freeze-dried reagent can be stored at room temperature or 2-8°C, which is more convenient to transport and store and has lower costs.

[0093] A twelve-panel respiratory pathogen test primer probe set, including:

[0094] Influenza A virus targets, including:

[0095] Upstream primer 5′-GGAGTYTTCGAGCTYTCRGAC-3′;

[0096] Downstream primer 5′-TCTGCATTGTCTCCRAAGAAATARG-3′;

[0097] Probe 5'5'-FAM-CCGATCGTGCCYTCYTTTGACATGA-3'BHQ1

[0098] Influenza B virus targets, including:

[0099] Upstream primer 5′-CTGAAACTGCGRTGGGAGTC-3′;

[0100] Downstream primer 5′-TTGTCTCCCTCTTCTGGTGAT-3′;

[0101] Probe 5′5′-ROX-TCCCAATTTGGTCAAGAGCACCGATT-3′BHQ2;

[0102] Adenoviral targets include:

[0103] Upstream primer 5′-GCTCCATGGCCTCRTARAAG-3′;

[0104] Downstream primer 5′-CGARCTCATCCGTCTTYTSG-3′;

[0105] Probe 5′CY5-CCACGGCRAARTTRAAAAACTGGGAGTT-3′BHQ3;

[0106] Novel coronavirus targets, including:

[0107] Upstream primer-15′-TCATCAGGAGATGCCACAAC-3′;

[0108] Downstream primer-15′-CGGCAATTTTGTTACCATCA-3′;

[0109] Probe-1 5′FAM-CTGTCACGGCCAATGTTAATGCA-3′BHQ1;

[0110] Upstream primer-25′-GTGATGCTGCTCTTGCTTTG-3′;

[0111] Downstream primer-25′-CCTTGTTGTTGTTGGCCTTT-3′;

[0112] Probe-2 5'5'-FAM-TGACAGATTGAACCAGCTTGAGAGCA-3'BHQ1; Coronavirus targets, including:

[0113] Upstream primer-15′-TTWTCTATCTAYAGATAGARAAKTT-3′;

[0114] Downstream primer-15′-GAAATTTCAATTACACTASGACT-3′;

[0115] Probe-1 5'5'-ROX-TTTAGACTTTGTGTCTACTYTTCTCAACT-3'BHQ2; Upstream primer-2 5'-CRCCTGTACAGGTTGTTGATTC-3';

[0116] Downstream primer-25′-CCATCWCCRTGRTTAATATCATA-3′;

[0117] Probe-2 5'5'-ROX-CCRTAYTGTTATTTTCGYAATTCTWCT-3'BHQ2; Respiratory Syncytial Virus target, including:

[0118] Upstream primer 5′-GGGCAAATATGGAAACDTACGTG-3′;

[0119] Downstream primer 5′-GATGCRGGRTCATCRTCTTTTTC-3′;

[0120] Probe 5′CY5-CTTCACGARGGCTCCACATACACAGC-3′BHQ3;

[0121] Rhinovirus targets, including:

[0122] Upstream primer 5′-GCCTGCGTGGCGGCCARC-3′;

[0123] Downstream primer 5′-CCCAAAGTAGTYGGTYCCRTC-3′;

[0124] Probe 5'FAM-TCCGGYCCCTGAATGYGGCTAA-3'BHQ1;

[0125] Parainfluenza virus targets, including:

[0126] Upstream primer-15′-TTTCTTAYAGTCTCAAAGAAAARG-3′;

[0127] Downstream primer-15′-ATCTCTCCCTTCACCATCCCATT-3′;

[0128] Probe-1 5′ROX-AACAAGARGGTAGACTCTTTGCAAARATGACA-3′BHQ2; Upstream primer-2 5′-AAATACTGTCTTMAWTGGAGATATC-3′;

[0129] Downstream primer-25′-ATGAATCCAYTCAAATAAATGWGG-3′;

[0130] Probe-2 5'5'-ROX-TTTGCTMGAACATTAAAYCGAATGTATGGA-3'BHQ2; Mycoplasma pneumoniae targets, including:

[0131] Upstream primer 5′-GTTGTTGGTGGARGAGGTGT-3′;

[0132] Downstream primer 5′-CCCGTTGAAAAAGTGAGTGG-3′;

[0133] Probe 5′CY5-CTTGGTAACTGCCCCACAAGCCAC-3′BHQ3;

[0134] Chlamydia pneumoniae targets, including:

[0135] Upstream primer 5′-AAGGGCTATAAAGGCGTTGCT-3′;

[0136] Downstream primer 5′-TGGTCGCAGACTTTGTTCCA-3′;

[0137] Probe 5′FAM-TCCCCTTGCCAACAGACGCTGG-3′BHQ1;

[0138] Streptococcus pneumoniae targets, including:

[0139] Upstream primer 5′-CCAACAAATCGTTTACCGCTC-3′;

[0140] Downstream primer 5′-TGGTTTGGCAAGTAGCGATAG-3′;

[0141] Probe 5′ROX-CACTCGAATTGCTGGGGTCTTCCACT-3′BHQ2;

[0142] Haemophilus influenzae targets, including:

[0143] Upstream primer 5′-GCCAAGAGATACTCATAGAACGT-3′;

[0144] Downstream primer 5′-TTTAGGGCGAAATGGTGCTG-3′;

[0145] Probe 5′CY5-TTGGAGGCTCAACACCASTCATCAAA-3′BHQ3;

[0146] RNaseP gene targets, including:

[0147] Upstream primer 5′-TTCTGGGGGTTGTTATCTGG-3′;

[0148] Downstream primer 5′-TCCGGCTTCTGTCACCTATC-3′;

[0149] Probe 5'VIC-AACGAGGGCGAGGGATTTGCAT-3'BHQ1.

[0150] A kit for detecting twelve respiratory pathogens, using a primer probe set for detecting twelve respiratory pathogens, including PCR freeze-dried balls 1 to 4, a negative control substance, and a positive control substance;

[0151] The PCR freeze-dried balls 1 to 4 include primer probe sets.

[0152] In this embodiment, the PCR freeze-dried pellet further includes at least one of PCR Buffer, Taq enzyme, UDG enzyme and reverse transcriptase.

[0153] In this embodiment, the negative control substance is physiological saline containing human genomic DNA.

[0154] In this embodiment, the positive control is a physiological saline containing human genomic DNA, influenza A virus, influenza B virus, adenovirus, new coronavirus, coronavirus, respiratory syncytial virus, rhinovirus, parainfluenza virus, Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptococcus pneumoniae, Haemophilus influenzae plasmid or pseudovirus.

[0155] Each component in the kit of the present invention, such as the primer probe, PCR Buffer, and enzyme in the PCR freeze-dried ball, are commercial reagents or raw materials, wherein the primer probe sequence is designed by the company itself and synthesized by a commissioned synthesis company; the plasmid or pseudovirus in the negative control and positive control is synthesized by a commissioned gene synthesis company with the sequence provided by the company, and the human genomic DNA is prepared by the company itself.

[0156] In this example, in the PCR freeze-dried beads 1 to 4, the final concentration of the primers was 0.1 μM, and the final concentration of the probes was 0.05 μM.

[0157] A method for detecting twelve respiratory pathogens, using a kit for detecting twelve respiratory pathogens, comprises the following steps:

[0158] a) Collect samples according to the standard sampling operation method for nasopharyngeal swabs and oropharyngeal swabs, and store them in nucleic acid release agents for later use;

[0159] b) Add the negative control substance, positive control substance and nucleic acid releasing agent in the kit in a ratio of 1:1 and mix well for later use;

[0160] c) taking 20 μl of each sample from step a) and step b) and adding them to the PCR reaction tubes containing freeze-dried balls 1 to 4 to fully dissolve them, flash centrifuging to ensure that there are no bubbles; placing them in a fluorescent quantitative PCR instrument for fluorescent PCR detection;

[0161] d) The reaction program was set as follows: Step 1: 55°C for 2-5 min; Step 2: 98°C for 1 min; Step 3: 98°C for 1-3 s, 60°C for 5-10 s, where Step 3 was set for 40 cycles and fluorescence (FAM / VIC / ROX / CY5) was read during 60°C for 5-10 s;

[0162] e) After PCR amplification, the analysis software of the fluorescent PCR instrument is used to analyze the results of the test samples, negative controls, and positive controls, and the fluorescence signal values ​​of the FAM / VIC / ROX / CY5 channels are used to determine the effectiveness of the experiment and the infection status of the twelve respiratory pathogens in the sample.

[0163] In this embodiment, the reaction program is set as follows: Step 1: 55°C for 2 min; Step 2: 98°C for 1 min; Step 3: 98°C for 1 s, 60°C for 5 s, wherein Step 3 is set for 40 cycles, and fluorescence (FAM / VIC / ROX / CY5) is read during 60°C for 5 s.

[0164] Through the above technical scheme, the primer probe set for detecting twelve respiratory pathogens provided by the present invention has high sensitivity, good specificity, covers a wide range of pathogens, and can meet the current clinical needs of diversified respiratory pathogen infections;

[0165] The kit provided by the present invention adopts the form of freeze-dried balls, which is more convenient to transport and store, does not require a complicated manual preparation process, and can be added with a 100% proportion of nucleic acid template, thereby improving the detection sensitivity; the freeze-dried ball reagent adopts an ultrafast PCR reaction system, which can realize a fast fluorescent PCR detection process;

[0166] The present invention provides a detection method for lysing a sample using a nucleic acid releaser, which does not require a cumbersome and time-consuming nucleic acid extraction process; it also provides an amplification procedure with a shorter reaction time. The entire detection process can be completed in about 50 minutes when used with the kit of the present invention, thereby improving the detection efficiency.

[0167] Example 2

[0168] A twelve-panel respiratory pathogen test primer probe set, including:

[0169] Influenza A virus targets, including:

[0170] Upstream primer 5′-GGAGTYTTCGAGCTYTCRGAC-3′;

[0171] Downstream primer 5′-TCTGCATTGTCTCCRAAGAAATARG-3′;

[0172] Probe 5'5'-FAM-CCGATCGTGCCYTCYTTTGACATGA-3'BHQ1

[0173] Influenza B virus targets, including:

[0174] Upstream primer 5′-CTGAAACTGCGRTGGGAGTC-3′;

[0175] Downstream primer 5′-TTGTCTCCCTCTTCTGGTGAT-3′;

[0176] Probe 5′5′-ROX-TCCCAATTTGGTCAAGAGCACCGATT-3′BHQ2;

[0177] Adenoviral targets include:

[0178] Upstream primer 5′-GCTCCATGGCCTCRTARAAG-3′;

[0179] Downstream primer 5′-CGARCTCATCCGTCTTYTSG-3′;

[0180] Probe 5′CY5-CCACGGCRAARTTRAAAAACTGGGAGTT-3′BHQ3;

[0181] Novel coronavirus targets, including:

[0182] Upstream primer-15′-TCATCAGGAGATGCCACAAC-3′;

[0183] Downstream primer-15′-CGGCAATTTTGTTACCATCA-3′;

[0184] Probe-1 5′FAM-CTGTCACGGCCAATGTTAATGCA-3′BHQ1;

[0185] Upstream primer-25′-GTGATGCTGCTCTTGCTTTG-3′;

[0186] Downstream primer-25′-CCTTGTTGTTGTTGGCCTTT-3′;

[0187] Probe-2 5'5'-FAM-TGACAGATTGAACCAGCTTGAGAGCA-3'BHQ1; Coronavirus targets, including:

[0188] Upstream primer-15′-TTWTCTATCTAYAGATAGARAAKTT-3′;

[0189] Downstream primer-15′-GAAATTTCAATTACACTASGACT-3′;

[0190] Probe-1 5'5'-ROX-TTTAGACTTTGTGTCTACTYTTCTCAACT-3'BHQ2; Upstream primer-2 5'-CRCCTGTACAGGTTGTTGATTC-3';

[0191] Downstream primer-25′-CCATCWCCRTGRTTAATATCATA-3′;

[0192] Probe-2 5'5'-ROX-CCRTAYTGTTATTTTCGYAATTCTWCT-3'BHQ2; Respiratory Syncytial Virus target, including:

[0193] Upstream primer 5′-GGGCAAATATGGAAACDTACGTG-3′;

[0194] Downstream primer 5′-GATGCRGGRTCATCRTCTTTTTC-3′;

[0195] Probe 5′CY5-CTTCACGARGGCTCCACATACACAGC-3′BHQ3;

[0196] Rhinovirus targets, including:

[0197] Upstream primer 5′-GCCTGCGTGGCGGCCARC-3′;

[0198] Downstream primer 5′-CCCAAAGTAGTYGGTYCCRTC-3′;

[0199] Probe 5'FAM-TCCGGYCCCTGAATGYGGCTAA-3'BHQ1;

[0200] Parainfluenza virus targets, including:

[0201] Upstream primer-15′-TTTCTTAYAGTCTCAAAGAAAARG-3′;

[0202] Downstream primer-15′-ATCTCTCCCTTCACCATCCCATT-3′;

[0203] Probe-1 5′ROX-AACAAGARGGTAGACTCTTTGCAAARATGACA-3′BHQ2; Upstream primer-2 5′-AAATACTGTCTTMAWTGGAGATATC-3′;

[0204] Downstream primer-25′-ATGAATCCAYTCAAATAAATGWGG-3′;

[0205] Probe-2 5'5'-ROX-TTTGCTMGAACATTAAAYCGAATGTATGGA-3'BHQ2; Mycoplasma pneumoniae targets, including:

[0206] Upstream primer 5′-GTTGTTGGTGGARGAGGTGT-3′;

[0207] Downstream primer 5′-CCCGTTGAAAAAGTGAGTGG-3′;

[0208] Probe 5′CY5-CTTGGTAACTGCCCCACAAGCCAC-3′BHQ3;

[0209] Chlamydia pneumoniae targets, including:

[0210] Upstream primer 5′-AAGGGCTATAAAGGCGTTGCT-3′;

[0211] Downstream primer 5′-TGGTCGCAGACTTTGTTCCA-3′;

[0212] Probe 5′FAM-TCCCCTTGCCAACAGACGCTGG-3′BHQ1;

[0213] Streptococcus pneumoniae targets, including:

[0214] Upstream primer 5′-CCAACAAATCGTTTACCGCTC-3′;

[0215] Downstream primer 5′-TGGTTTGGCAAGTAGCGATAG-3′;

[0216] Probe 5′ROX-CACTCGAATTGCTGGGGTCTTCCACT-3′BHQ2;

[0217] Haemophilus influenzae targets, including:

[0218] Upstream primer 5′-GCCAAGAGATACTCATAGAACGT-3′;

[0219] Downstream primer 5′-TTTAGGGCGAAATGGTGCTG-3′;

[0220] Probe 5′CY5-TTGGAGGCTCAACACCASTCATCAAA-3′BHQ3;

[0221] RNaseP gene targets, including:

[0222] Upstream primer 5′-TTCTGGGGGTTGTTATCTGG-3′;

[0223] Downstream primer 5′-TCCGGCTTCTGTCACCTATC-3′;

[0224] Probe 5'VIC-AACGAGGGCGAGGGATTTGCAT-3'BHQ1.

[0225] A kit for detecting twelve respiratory pathogens, using a primer probe set for detecting twelve respiratory pathogens, including PCR freeze-dried balls 1 to 4, a negative control substance, and a positive control substance;

[0226] The PCR freeze-dried balls 1 to 4 include primer probe sets.

[0227] In this embodiment, the PCR freeze-dried pellet further includes at least one of PCR Buffer, Taq enzyme, UDG enzyme and reverse transcriptase.

[0228] In this embodiment, the negative control substance is physiological saline containing human genomic DNA.

[0229] In this embodiment, the positive control is a physiological saline containing human genomic DNA, influenza A virus, influenza B virus, adenovirus, new coronavirus, coronavirus, respiratory syncytial virus, rhinovirus, parainfluenza virus, Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptococcus pneumoniae, Haemophilus influenzae plasmid or pseudovirus.

[0230] In this example, in the PCR freeze-dried beads 1 to 4, the final concentration of the primers was 0.4 μM, and the final concentration of the probes was 0.2 μM.

[0231] A method for detecting twelve respiratory pathogens, using a kit for detecting twelve respiratory pathogens, comprises the following steps:

[0232] a) Collect samples according to the standard sampling operation method for nasopharyngeal swabs and oropharyngeal swabs, and store them in nucleic acid release agents for later use;

[0233] b) Add the negative control substance, positive control substance and nucleic acid releasing agent in the kit in a ratio of 1:1 and mix well for later use;

[0234] c) taking 20 μl of each sample from step a) and step b) and adding them to the PCR reaction tubes containing freeze-dried balls 1 to 4 to fully dissolve them, flash centrifuging to ensure that there are no bubbles; placing them in a fluorescent quantitative PCR instrument for fluorescent PCR detection;

[0235] d) The reaction program was set as follows: Step 1: 55°C for 2-5 min; Step 2: 98°C for 1 min; Step 3: 98°C for 1-3 s, 60°C for 5-10 s, where Step 3 was set for 40 cycles and fluorescence (FAM / VIC / ROX / CY5) was read during 60°C for 5-10 s;

[0236] e) After PCR amplification, the analysis software of the fluorescent PCR instrument is used to analyze the results of the test samples, negative controls, and positive controls, and the fluorescence signal values ​​of the FAM / VIC / ROX / CY5 channels are used to determine the effectiveness of the experiment and the infection status of the twelve respiratory pathogens in the sample.

[0237] In this embodiment, the reaction program is set as follows: Step 1: 55°C for 5 min; Step 2: 98°C for 1 min; Step 3: 98°C for 3 s, 60°C for 10 s, wherein Step 3 is set for 40 cycles, and fluorescence (FAM / VIC / ROX / CY5) is read during 60°C for 10 s.

[0238] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A primer probe set for detecting twelve respiratory pathogens, characterized in that: include: Influenza A virus targets, including: Upstream primer 5′-GGAGTYTTCGAGCTYTCRGAC-3′; Downstream primer 5′-TCTGCATTGTCTCCRAAGAAATARG-3′; Probe 5'5'-FAM-CCGATCGTGCCYTCYTTTGACATGA-3'BHQ1 Influenza B virus targets, including: Upstream primer 5′-CTGAAACTGCGRTGGGAGTC-3′; Downstream primer 5′-TTGTCTCCCTCTTCTGGTGAT-3′; Probe 5′5′-ROX-TCCCAATTTGGTCAAGAGCACCGATT-3′BHQ2; Adenoviral targets include: Upstream primer 5′-GCTCCATGGCCTCRTARAAG-3′; Downstream primer 5′-CGARCTCATCCGTCTTYTSG-3′; Probe 5′CY5-CCACGGCRAARTTRAAAAACTGGGAGTT-3′BHQ3; Novel coronavirus targets, including: Upstream primer-15′-TCATCAGGAGATGCCACAAC-3′; Downstream primer-15′-CGGCAATTTTGTTACCATCA-3′; Probe-1 5′FAM-CTGTCACGGCCAATGTTAATGCA-3′BHQ1; Upstream primer-25′-GTGATGCTGCTCTTGCTTTG-3′; Downstream primer-25′-CCTTGTTGTTGTTGGCCTTT-3′; Probe-2 5′5′-FAM-TGACAGATTGAACCAGCTTGAGAGCA-3′BHQ1; Coronavirus targets, including: Upstream primer-15′-TTWTCTATCTAYAGATAGARAAKTT-3′; Downstream primer-15′-GAAATTTCAATTACACTASGACT-3′; Probe-1 5′5′-ROX-TTTAGACTTTGTGTCTACTYTTCTCAACT-3′BHQ2; Upstream primer-25′-CRCCTGTACAGGTTGTTGATTC-3′; Downstream primer-25′-CCATCWCCRTGRTTAATATCATA-3′; Probe-2 5′5′-ROX-CCRTAYTGTTATTTTCGYAATTCTWCT-3′BHQ2; Respiratory syncytial virus targets, including: Upstream primer 5′-GGGCAAATATGGAAACDTACGTG-3′; Downstream primer 5′-GATGCRGGRTCATCRTCTTTTTC-3′; Probe 5′CY5-CTTCACGARGGCTCCACATACACAGC-3′BHQ3; Rhinovirus targets, including: Upstream primer 5′-GCCTGCGTGGCGGCCARC-3′; Downstream primer 5′-CCCAAAGTAGTYGGTYCCRTC-3′; Probe 5'FAM-TCCGGYCCCTGAATGYGGCTAA-3'BHQ1; Parainfluenza virus targets, including: Upstream primer-15′-TTTCTTAYAGTCTCAAAGAAAARG-3′; Downstream primer-15′-ATCTCTCCCTTCACCATCCCATT-3′; Probe-1 5′ROX-AACAAGARGGTAGACTCTTTGCAAARATGACA-3′BHQ2; Upstream primer-2 5′-AAATACTGTCTTMAWTGGAGATATC-3′; Downstream primer-25′-ATGAATCCAYTCAAATAAATGWGG-3′; Probe-2 5'5'-ROX-TTTGCTMGAACATTAAAYCGAATGTATGGA-3'BHQ2; Mycoplasma pneumoniae targets, including: Upstream primer 5′-GTTGTTGGTGGARGAGGTGT-3′; Downstream primer 5′-CCCGTTGAAAAAGTGAGTGG-3′; Probe 5′CY5-CTTGGTAACTGCCCCACAAGCCAC-3′BHQ3; Chlamydia pneumoniae targets, including: Upstream primer 5′-AAGGGCTATAAAGGCGTTGCT-3′; Downstream primer 5′-TGGTCGCAGACTTTGTTCCA-3′; Probe 5′FAM-TCCCCTTGCCAACAGACGCTGG-3′BHQ1; Streptococcus pneumoniae targets, including: Upstream primer 5′-CCAACAAATCGTTTACCGCTC-3′; Downstream primer 5′-TGGTTTGGCAAGTAGCGATAG-3′; Probe 5′ROX-CACTCGAATTGCTGGGGTCTTCCACT-3′BHQ2; Haemophilus influenzae targets, including: Upstream primer 5′-GCCAAGAGATACTCATAGAACGT-3′; Downstream primer 5′-TTTAGGGCGAAATGGTGCTG-3′; Probe 5′CY5-TTGGAGGCTCAACACCASTCATCAAA-3′BHQ3; RNaseP gene targets, including: Upstream primer 5′-TTCTGGGGGTTGTTATCTGG-3′; Downstream primer 5′-TCCGGCTTCTGTCACCTATC-3′; Probe 5'VIC-AACGAGGGCGAGGGATTTGCAT-3'BHQ1.

2. A kit for detecting twelve respiratory pathogens, using the primer probe set for detecting twelve respiratory pathogens according to claim 1, characterized in that: Includes PCR freeze-dried beads 1 to 4, negative control, and positive control; The PCR freeze-dried balls 1 to 4 include primer probe sets.

3. A kit for detecting twelve respiratory pathogens according to claim 2, characterized in that: The PCR freeze-dried pellet also includes at least one of PCR Buffer, Taq enzyme, UDG enzyme and reverse transcriptase.

4. A kit for detecting twelve respiratory pathogens according to claim 2, characterized in that: The negative control substance is physiological saline containing human genomic DNA.

5. A kit for detecting twelve respiratory pathogens according to claim 4, characterized in that: The positive control is a physiological saline containing human genomic DNA, influenza A virus, influenza B virus, adenovirus, new coronavirus, coronavirus, respiratory syncytial virus, rhinovirus, parainfluenza virus, Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptococcus pneumoniae, Haemophilus influenzae plasmid or pseudovirus.

6. A kit for detecting twelve respiratory pathogens according to claim 2, characterized in that: In the PCR freeze-dried balls 1 to 4, the final concentration of the primers is 0.1 to 0.4 μM, and the final concentration of the probes is 0.05 to 0.2 μM.

7. A method for detecting twelve respiratory pathogens, using a kit for detecting twelve respiratory pathogens according to any one of claims 2 to 6, characterized in that: The following steps are involved: a) Collect samples according to the standard sampling operation method for nasopharyngeal swabs and oropharyngeal swabs, and store them in nucleic acid release agents for later use; b) Add the negative control substance, positive control substance and nucleic acid release agent in the kit in a ratio of 1:1 and mix well for later use; c) taking 20 μl of the samples in step a) and step b) and adding them to the PCR reaction tubes containing freeze-dried balls 1 to 4 to fully dissolve them, flash centrifuging to ensure that there are no bubbles; placing them in a fluorescent quantitative PCR instrument for fluorescent PCR detection; d) The reaction program was set as follows: Step 1: 55°C for 2-5 min; Step 2: 98°C for 1 min; Step 3: 98°C for 1-3 s, 60°C for 5-10 s, where Step 3 was set for 40 cycles and fluorescence (FAM / VIC / ROX / CY5) was read during 60°C for 5-10 s; e) After PCR amplification, the analysis software of the fluorescent PCR instrument is used to analyze the results of the test samples, negative controls, and positive controls, and the fluorescence signal values ​​of the FAM / VIC / ROX / CY5 channels are used to determine the effectiveness of the experiment and the infection status of the twelve respiratory pathogens in the sample.

8. A detection method for detecting twelve respiratory pathogens according to claim 7, characterized in that: The reaction program was set as follows: Step 1: 55°C for 2 min; Step 2: 98°C for 1 min; Step 3: 98°C for 1 s, 60°C for 5 s, wherein Step 3 was set for 40 cycles, and fluorescence (FAM / VIC / ROX / CY5) was read during 60°C for 5 s.

9. A detection method for detecting twelve respiratory pathogens according to claim 7, characterized in that: The reaction program was set as follows: Step 1: 55°C for 5 min; Step 2: 98°C for 1 min; Step 3: 98°C for 3 s, 60°C for 10 s, wherein Step 3 was set for 40 cycles, and fluorescence (FAM / VIC / ROX / CY5) was read during 60°C for 10 s.

Citation Information

Cited By

  • Kit and method for detecting influenza A virus and respiratory syncytial virus

    CN119220744A

  • Nucleic acid composition for respiratory tract pathogen detection and application thereof

    CN119913289A